High radiation dose in chemoradiotherapy followed by immunotherapy with durvalumab in patients with stage III non-small cell lung cancer does not increase risk for pneumonitis
Recent Publication
A new study at Krems University Hospital has investigated whether a higher radiation dose is beneficial in the treatment of non-small cell lung cancer (NSCLC). Patients who were treated with the immunotherapy drug durvalumab following combined radiotherapy and chemotherapy received either a standard radiation dose or a higher dose of 70 Gy. The results show that the higher radiation dose significantly improves the chances of survival without increasing the risk of pneumonia.
Schragel, F., Matousek, M., Resl, C., Kreye, G., Le, N.-S., Errhalt, P., Georg, P., & Hackner, K. (2025). High radiation dose in chemoradiotherapy followed by immunotherapy with durvalumab in patients with stage III non-small cell lung cancer does not increase risk for pneumonitis. Strahlentherapie und Onkologie. Advance online publication. https://doi.org/10.1007/s00066-025-02369-0
OA Dr. Felix Schragel
Division of Pneumology (University Hospital Krems)
OA Dr. Christoph Resl
Division of Radiotherapy - Radiation Oncology (University Hospital Krems)
OÄ PD Dr. Gudrun Kreye MBA
Division of Internal Medicine 2 (University Hospital Krems)
OA Dr. Nguyen-Son Le
Division of Internal Medicine 2 (University Hospital Krems)
Prim. Clin. Ass. Prof. Dr. Peter Errhalt
Division of Pneumology (University Hospital Krems)
Prim. Clin. Assoc. Prof. PD Dr. Petra Georg MBA
Division of Radiotherapy - Radiation Oncology (University Hospital Krems)
OA Clin. Ass. Prof. DDr. Klaus Hackner MSc
Division of Pneumology (University Hospital Krems)